Preclinical studies reveal that dual checkpoint blockade with anti-PD1 and anti-CTLA4 decreases replacement of T effector cells with T regulatory cells, enhances dendritic cell activation, and increases activation of tumor-infiltrating cytotoxic CD8+ and CD4+ T cells [14,16]. The gene discussed is CD8A; the disease is neoplasm.